Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders
- 30 November 2020
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 36 (3), e2772
- https://doi.org/10.1002/hup.2772
Abstract
Objective Some studies have linked the use of selective serotonin reuptake inhibitors and selective serotonin and noradrenaline reuptake inhibitors (SSRIs/SNRIs) to the risk of perinatal complications. This study explored the relationship between pharmacokinetics and pharmacogenetics, SSRIs/SNRIs tolerability and effectiveness and maternal and newborn outcomes. Methods Fifty‐five pregnant women with Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM‐5) diagnoses of affective disorders, treated with SSRIs/SNRIs, were recruited and, during the third trimester, their blood samples were collected for pharmacokinetic and pharmacogenetic analyses. Plasma levels and metabolic phenotypes were then related to different obstetrical and maternal outcomes. Results The pharmacokinetic data were more stable for Sertraline, Citalopram, and Escitalopram compared to other molecules (p = 0.009). The occurrence of postnatal adaptation syndrome onset was associated with higher plasma levels for Sertraline (median at delivery: 16.7 vs. 10.5 ng/ml), but not for fluoxetine and venlafaxine. Finally, the subgroup within range plasma concentrations had less blood loss than the below range subgroup (p = 0.030). Conclusions Plasma levels of Sertraline, Citalopram and Escitalopram were more frequently in range in late pregnancy when compared to other drugs. Drug plasma concentrations do not strictly correlate with worse perinatal outcomes, but with possible differences between the different drugs.Keywords
This publication has 50 references indexed in Scilit:
- Fluoxetine pharmacogenetics in child and adult populationsEuropean Child & Adolescent Psychiatry, 2012
- Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal PregnancyClinical Pharmacokinetics, 2012
- Serotonin Reuptake Inhibitor Antidepressants and Abnormal BleedingBritish Journal of Psychology, 2010
- Characterization of Serotonin Receptors in Pregnant Human MyometriumThe Journal of pharmacology and experimental therapeutics, 2008
- The Risk of Postpartum Hemorrhage With Selective Serotonin Reuptake Inhibitors and Other AntidepressantsJournal of Clinical Psychopharmacology, 2008
- Fear of Childbirth and Pregnancy-Related Anxiety in Women Conceiving With Assisted ReproductionObstetrics & Gynecology, 2006
- Perinatal DepressionObstetrics & Gynecology, 2005
- Treatment with Selective Serotonin Reuptake Inhibitors in the Third Trimester of PregnancyDrug Safety, 2005
- Serum disposition of sertraline, N‐desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depressionHuman Psychopharmacology: Clinical and Experimental, 2004
- Effects of Venlafaxine on Blood PressureBritish Journal of Psychology, 1998